MonoSol Rx expands nanoparticle pact with Midatech; EyeGate launches pivotal trial

>  Drug delivery tech outfit MonoSol Rx expanded its pact with Midatech Group in the UK to develop nanoparticle-based proteins and peptides for therapeutic delivery using pharmaceutical films. Release

> MonoSol also announced that it has named Eric Dadey senior vice president, pharmaceutical development. Release

> Archimedes Pharma received a positive opinion from the Committee for Human Medicinal Products of the European Medicines Agency recommending PecFent, a fentanyl nasal spray, for the treatment of breakthrough cancer pain. Release

> EyeGate Pharma, which is developing a non-invasive ocular drug delivery platform and ocular drugs, has begun enrolling patients in the pivotal Phase III study of its lead product, EGP-437, for the treatment of Dry Eye Syndrome. Release

> Innomech has struck a deal to develop an end-of-line testing system for a new drug delivery pen. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.